Biosimilar Threat Looms For J&J, Amgen And Others, Decision Resources Forecasts
This article was originally published in The Pink Sheet Daily
Executive Summary
J&J and Amgen are the drug makers that will lose the largest percent of cumulative revenues to biosimilars from 2009 to 2019, the research firm estimates.
You may also be interested in...
Biosimilars On The Horizon: How Much Will FDA Look To The East?
Europe's pathway for follow-on biologics has selling points for both brand and generic firms, but FDA will chart its own course - even as it mulls accepting European data.
Biosimilars On The Horizon: How Much Will FDA Look To The East?
Europe's pathway for follow-on biologics has selling points for both brand and generic firms, but FDA will chart its own course - even as it mulls accepting European data.
Opening A Door To Biosimilars In The US
With the regulatory door ajar, companies across the pharmaceutical industry are vying to dominate the biosimilars space, despite the commercial risks.